{"title":"钾绑定","authors":"M. Tinawi","doi":"10.26502/aimr.0034","DOIUrl":null,"url":null,"abstract":"Sodium polystyrene sulfonate was approved by the FDA in 1958. It was the only potassium binder available on the market until 2015. Patiromer and sodium zirconium cyclosilicate are newly approved potassium binders. They are better tolerated and can be used on a chronic basis to mitigate hyperkalemia. They allow patients to continue to use critical medications such as ACE inhibitors even in advanced chronic kidney disease.","PeriodicalId":8282,"journal":{"name":"Archives of Internal Medicine Research","volume":"31 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Potassium Binders\",\"authors\":\"M. Tinawi\",\"doi\":\"10.26502/aimr.0034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sodium polystyrene sulfonate was approved by the FDA in 1958. It was the only potassium binder available on the market until 2015. Patiromer and sodium zirconium cyclosilicate are newly approved potassium binders. They are better tolerated and can be used on a chronic basis to mitigate hyperkalemia. They allow patients to continue to use critical medications such as ACE inhibitors even in advanced chronic kidney disease.\",\"PeriodicalId\":8282,\"journal\":{\"name\":\"Archives of Internal Medicine Research\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Internal Medicine Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26502/aimr.0034\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Internal Medicine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/aimr.0034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Sodium polystyrene sulfonate was approved by the FDA in 1958. It was the only potassium binder available on the market until 2015. Patiromer and sodium zirconium cyclosilicate are newly approved potassium binders. They are better tolerated and can be used on a chronic basis to mitigate hyperkalemia. They allow patients to continue to use critical medications such as ACE inhibitors even in advanced chronic kidney disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
